Rigel Pharmaceuticals (RIGL) Leases (2019 - 2026)

Rigel Pharmaceuticals has reported Leases for 8 years, with the latest figure at $785000.0 in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 39.85% year-over-year to $785000.0; the trailing twelve-month figure through Mar 2026 stood at $785000.0 (down 39.85% YoY), and the FY2025 full-year result was $920000.0, up 273.98% from the prior year.
• Leases for Q1 2026 stood at $785000.0, down from $920000.0 in the prior quarter.
• The five-year high for Leases was $7.5 million in Q1 2022, with the low at $246000.0 in Q4 2024.
• Average Leases over 5 years is $1.7 million, with a median of $1.0 million recorded in 2023.
• Year-over-year, Leases sank 85.03% in 2023 and soared 273.98% in 2025.
• Tracing RIGL's Leases over 5 years: stood at $1.9 million in 2022, then sank by 55.39% to $861000.0 in 2023, then sank by 71.43% to $246000.0 in 2024, then soared by 273.98% to $920000.0 in 2025, then fell by 14.67% to $785000.0 in 2026.
• The last three Leases figures came in at $785000.0 (Q1 2026), $920000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.

Peer Comparison